418 reports of this reaction
4.2% of all ATOGEPANT reports
#5 most reported adverse reaction
CONSTIPATION is the #5 most commonly reported adverse reaction for ATOGEPANT, manufactured by AbbVie Inc.. There are 418 FDA adverse event reports linking ATOGEPANT to CONSTIPATION. This represents approximately 4.2% of all 9,899 adverse event reports for this drug.
Patients taking ATOGEPANT who experience constipation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONSTIPATION is moderately reported among ATOGEPANT users, representing a notable but not dominant share of adverse events.
In addition to constipation, the following adverse reactions have been reported for ATOGEPANT:
The following drugs have also been linked to constipation in FDA adverse event reports:
CONSTIPATION has been reported as an adverse event in 418 FDA reports for ATOGEPANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONSTIPATION accounts for approximately 4.2% of all adverse event reports for ATOGEPANT, making it a notable side effect.
If you experience constipation while taking ATOGEPANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.